These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 15280347)

  • 1. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
    Hofbauer LC; Schoppet M
    JAMA; 2004 Jul; 292(4):490-5. PubMed ID: 15280347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
    Kostenuik PJ
    Curr Opin Pharmacol; 2005 Dec; 5(6):618-25. PubMed ID: 16188502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical implications of new insights into the regulation of bone resorption].
    Lems WF; Bijlsma JW
    Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1664-7. PubMed ID: 16104110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).
    Hofbauer LC
    Ann Endocrinol (Paris); 2006 Apr; 67(2):139-41. PubMed ID: 16639364
    [No Abstract]   [Full Text] [Related]  

  • 6. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE; Bonnelye E
    Osteoporos Int; 2000; 11(11):905-13. PubMed ID: 11193242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.
    Hofbauer LC; Neubauer A; Heufelder AE
    Cancer; 2001 Aug; 92(3):460-70. PubMed ID: 11505389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Osteoprotegerin--a neutralizing receptor, protector of bones and a potential antiresorptive agent].
    Andelković Z; Katić V; Mihajlović D; Zivković V; Petrović A; Lalosević D
    Med Pregl; 2005; 58(7-8):362-7. PubMed ID: 16296579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE; Bonnelye E
    Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
    Hofbauer LC; Heufelder AE
    J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
    Anandarajah AP; Schwarz EM
    J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.
    Sattler AM; Schoppet M; Schaefer JR; Hofbauer LC
    Calcif Tissue Int; 2004 Jan; 74(1):103-6. PubMed ID: 14523602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
    Collin-Osdoby P
    Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N; Colla S; Rizzoli V
    Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function.
    Schoppet M; Preissner KT; Hofbauer LC
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):549-53. PubMed ID: 11950689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
    Tanaka S; Nakamura K; Takahasi N; Suda T
    Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
    Mochizuki S; Kiyokawa A; Nagayama Y
    Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment?
    Coetzee M; Kruger MC
    South Med J; 2004 May; 97(5):506-11. PubMed ID: 15180028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of a role for RANKL in the development of myeloma bone disease.
    De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI
    Curr Opin Pharmacol; 2004 Aug; 4(4):340-6. PubMed ID: 15251126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
    Vega D; Maalouf NM; Sakhaee K
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.